OraSure Technologies (NASDAQ:OSUR) Lowered to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report report published on Thursday.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR opened at $3.71 on Thursday. The stock has a market cap of $276.74 million, a PE ratio of 24.73 and a beta of 0.05. OraSure Technologies has a 1 year low of $3.52 and a 1 year high of $8.33. The firm has a fifty day moving average price of $3.88 and a 200-day moving average price of $4.12.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The firm had revenue of $39.92 million during the quarter, compared to analyst estimates of $38.97 million. During the same quarter in the prior year, the company posted $0.27 earnings per share. The business’s quarterly revenue was down 55.2% compared to the same quarter last year. On average, research analysts expect that OraSure Technologies will post -0.08 EPS for the current year.

Institutional Trading of OraSure Technologies

A number of large investors have recently added to or reduced their stakes in OSUR. American Century Companies Inc. grew its holdings in shares of OraSure Technologies by 30.1% in the second quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock valued at $7,710,000 after purchasing an additional 418,603 shares in the last quarter. WINTON GROUP Ltd increased its holdings in shares of OraSure Technologies by 61.4% in the 2nd quarter. WINTON GROUP Ltd now owns 210,581 shares of the medical instruments supplier’s stock worth $897,000 after buying an additional 80,113 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of OraSure Technologies during the 2nd quarter valued at about $1,602,000. Renaissance Technologies LLC lifted its holdings in shares of OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock valued at $9,749,000 after acquiring an additional 391,100 shares during the last quarter. Finally, Hsbc Holdings PLC grew its position in OraSure Technologies by 470.6% in the second quarter. Hsbc Holdings PLC now owns 200,779 shares of the medical instruments supplier’s stock worth $850,000 after acquiring an additional 165,590 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.